We suggest that the design of future trials of IL‐6 signalling inhibitors in asthma should consider a drug dose, administration route and/or timing that results in adequate drug availability in the lung; selective recruitment of asthmatics with mixed‐granulocytic inflammation; and drugs that block sIL‐6R but not mIL‐6R. This evidence concerns the gene IL6R and asthma.